MannKind
Logotype for MannKind Corporation

MannKind (MNKD) investor relations material

MannKind Corporate presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for MannKind Corporation
Corporate presentation summary10 Jan, 2026

Strategic focus and innovation

  • Emphasizes patient-centric solutions for cardiometabolic and orphan lung diseases, leveraging innovative drug delivery platforms.

  • Key pillars include Tyvaso DPI, FUROSCIX, and Afrezza, each targeting significant unmet needs and growth opportunities.

  • Technosphere technology underpins two FDA-approved products, enabling efficient deep lung drug delivery.

Product portfolio and pipeline

  • FUROSCIX offers a wearable, at-home diuretic for CHF/CKD, with strong revenue and dose growth; ReadyFlow autoinjector could further expand market reach pending 2026 approval.

  • Afrezza, an inhaled insulin, is recognized in ADA 2026 guidelines and is positioned for pediatric expansion with a PDUFA date in May 2026.

  • Tyvaso DPI continues to drive revenue growth, with new formulations and expanded collaboration with United Therapeutics.

  • Nintedanib DPI is advancing in Phase 2 for IPF, targeting a market with high unmet need due to current therapy limitations.

Financial performance and market opportunity

  • FUROSCIX net revenue reached $47.1M YTD Q3 2025, up 93% YoY, with 61,407 doses dispensed, up 153% YoY.

  • Afrezza net revenue was $51.7M YTD Q3 2025, up 23% YoY, with 31% YoY growth in new prescriptions.

  • Tyvaso DPI-related revenue was $954M YTD Q3 2025, up 22% YoY, with Q3 revenue of $59M, up 15% from Q3 2024.

  • Each 10% pediatric share for Afrezza could yield ~$150M in revenue; every 100K FUROSCIX patients is ~$350M in revenue.

Quantify ReadyFlow's COGS reduction potential
Basis for Afrezza pediatric revenue projections
How Nintedanib DPI addresses IPF therapy issues
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next MannKind earnings date

Logotype for MannKind Corporation
Q4 202523 Feb, 2026
MannKind
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next MannKind earnings date

Logotype for MannKind Corporation
Q4 202523 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage